Circio Secures Additional Funding for RNA Technology and Cancer Vaccine Trials

Targovax ASA ( (GB:0RIS) ) has issued an announcement.

Circio Holding ASA has exercised its option under a financing agreement with Atlas to secure an additional NOK 4,000,000 through convertible bonds, ensuring operational funding until June 2025. This move strengthens Circio’s financial position, supporting its innovative RNA technology development and ongoing cancer vaccine trials, potentially enhancing its market standing and providing low-cost future opportunities.

More about Targovax ASA

Circio Holding ASA is a biotechnology company focused on developing advanced circular RNA vector expression technology for nucleic acid medicine. Their proprietary circVec platform enhances protein expression significantly compared to traditional mRNA systems and is used in various therapeutic applications, including genetic medicine and chronic disease. Additionally, Circio is working on a pan-RAS cancer vaccine, TG01, targeting KRAS mutations, with ongoing clinical trials in the USA and Norway.

Average Trading Volume: 1,111,100

Current Market Cap: NOK63.39M

For a thorough assessment of 0RIS stock, go to TipRanks’ Stock Analysis page.